Whatever kind of life sciences company you are, it’s important to get your message out there and communicate your work to the right people. Media coverage can be an excellent way to do that, but getting interest from the top publications can be harder than it looks.
In August, we hosted the One Nucleus ‘BioWednesday’ event, inviting four leading life sciences journalists to share their industry insights, hearing from Clive Cookson, Financial Times; Amber Tong, Endpoints; Lucie Ellis, In Vivo; and Sabah Meddings, Sunday Times. Here, we share their top tips on how to create great stories and secure coverage.
Congratulations to our clients Fstar, Hookipa and Microbiotica, each pioneering disruptive technologies for the development of tomorrow’s therapeutics. They have announced bio-dollar deals collectively worth up to ~$1.4 billion.
MiFID II. An acronym that instils a broad set of emotions across the City of London, ranging from blind panic in some quarters to mild indifference in others. This widely quoted but little understood abbreviation of the second Markets in Financial Instruments Directive is already having an effect across the industry. However, the fact that each financial institution is interpreting the regulations in different ways show the level of confusion, with some continuing as if nothing has changed, whilst others feel that sending a piece of research to a PR is an invitation to buy or sell shares.